Dahms Bradford D. — SEC Form 4 filings

SEC reporting owner CIK 1787307. 3 Form 4 filings on record with FilingPulse; latest filed 2026-02-13.

Transaction summary — filings shown

Covers all 3 filings on record, filed 2024-02-14 to 2026-02-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Jade Biosciences, Inc. (JBIO)Chief Financial Officer23
Theseus Pharmaceuticals, Inc. (THRX)President and CFO13

Form 4 filings — Dahms Bradford D.

FiledFormIssuerReported transactionsSource
2026-02-134Jade Biosciences, Inc. (JBIO)Grant/award (A): 37,813 @ $0 · Grant/award (A): 226,875 (derivative) @ $0EDGAR
2025-07-144Jade Biosciences, Inc. (JBIO)Grant/award (A): 526,000 (derivative) @ $0EDGAR
2024-02-144Theseus Pharmaceuticals, Inc. (THRX)Code (U): 8,150.23 · Disposition to issuer (D): 17,500 (derivative) · Disposition to issuer (D): 332,114 (derivative)EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1787307 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →